三九医药2005年半年度报告（节录）_医药资讯

财务资料1、主要会计数据及财务指标单位：人民币元本报告期末上年度期末本报告期末比年初数增减（％）流动资产5,425,031,831.705,575,317,822.24-2.70流动负债4,580,893,106.094,821,664,087.10-4.99总资产6,994,742,780.427,177,607,192.83-2.55股东权益（不含少数股东权益）2,174,661,264.492,113,879,359.622.88每股净资产2.222.162.78调整后的每股净资产0.500.55-9.09报告期（1－6月）上年同期本报告期比上年同期增减（％）净利润60,781,904.8790,418,313.70-32.78扣除非经常性损益后的净利润32,121,962.9263,425,943.21-49.36每股收益0.06210.0924-32.78净资产收益率2.80%3.01%-0.21经营活动产生的现金流量净额-26,914,422.7231,200,213.45-186.262、扣除非经常性损益项目和金额单位：人民币元非经常性损益项目金额计提各项减值准备的转回0.00对非金融企业收取的资金占用费25,210,371.43其他各项营业外收入4,884,843.95扣除资产减值后其他各项营业外支出-1,435,273.44合计28,659,941.953、利润及利润分配表单位：人民币元项 目合并数母公司2005年1-6月2004年1-6月2005年1-6月2004年1-6月一、主营业务收入1,391,722,266.991,364,495,579.60416,171,528.48333,871,748.64减：主营业务成本753,419,580.54758,165,834.29151,122,715.41118,613,872.79主营业务税金及附加6,850,956.773,644,863.662,385,283.931,524,470.72二、主营业务利润631,451,729.68602,684,881.65262,663,529.14213,733,405.13加：其他业务利润12,572,170.095,933,219.84496,366.111,152,208.95减：营业费用319,885,068.52263,624,647.1758,884,562.2522,643,103.31管理费用165,792,596.37164,730,489.6530,229,902.7152,950,039.30财务费用65,871,507.2463,939,344.4452,079,668.2047,070,715.50三、营业利润92,474,727.64116,323,620.23121,965,762.0992,221,755.97加：投资收益-11,870,300.21-10,517,843.96-18,433,432.87-15,682,875.57补贴收入26,780.00营业外收入8,990,485.802,210,324.42286,329.56349,555.11减：营业外支出1,764,111.201,976,431.7344,024.32378,059.91四、利润总额87,857,582.03106,039,668.96103,774,634.4676,510,375.60减：所得税23,552,008.6818,041,431.9618,571,041.7911,718,564.57减：少数股东损益3,523,668.48-2,420,076.70五、净利润60,781,904.8790,418,313.7085,203,592.6764,791,811.03加：年初未分配利润-484,789,446.64322,792,288.80-475,070,886.91345,042,401.16其他转入六、可供分配的利润-424,007,541.77413,210,602.50-389,867,294.24409,834,212.19减：提取法定盈余公积提取法定公益金提取职工福利奖励基金七、可供股东分配的利润-424,007,541.77413,210,602.50-389,867,294.24409,834,212.19减：应付优先股股利提取任意盈余公积应付普通股股利转作股本的普通股股利八、未分配利润-424,007,541.77413,210,602.50-389,867,294.24409,834,212.19补充资料1、出售、处置部门或被投资单位所得收益2、自然灾害发生的损失3、会计政策变更增加（或减少）利润总额4、会计估计变更增加（或减少）利润总额5、债务重组损失6、其他 详见《三九医药股份有限公司2005年半年度报告》（据“深圳证券交易所”；医药网整理，严禁转载）

本文来源于网络，版权归作者所有，如有侵权请联系网站客服。